Weighted Average Number of Shares Outstanding, Diluted of SEELOS THERAPEUTICS, INC. from 30 Jun 2013 to 30 Jun 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
SEELOS THERAPEUTICS, INC. quarterly and annual Weighted Average Number of Shares Outstanding, Diluted in shares history and change rate from 30 Jun 2013 to 30 Jun 2024.
  • SEELOS THERAPEUTICS, INC. Weighted Average Number of Shares Outstanding, Diluted for the quarter ending 30 Jun 2024 was 2,515,400, a 358% increase year-over-year.
  • SEELOS THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 4,900,222, a 38% increase from 2022.
  • SEELOS THERAPEUTICS, INC. annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 3,545,691, a 96% decline from 2021.
Source SEC data
View on sec.gov
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Change (%)
Weighted Average Number of Shares Outstanding, Diluted, Annual (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Annual Change (%)

SEELOS THERAPEUTICS, INC. Quarterly Weighted Average Number of Shares Outstanding, Diluted (shares)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q2 2024 2,515,400 +1,965,705 +358% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2024 2024 Q2
Q1 2024 13,007,556 +9,256,088 +247% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 4,900,222 +1,354,531 +38% 01 Oct 2023 31 Dec 2023 10-K 06 Mar 2024 2023 FY
Q3 2023 148,138,721 +41,448,797 +39% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2023 2023 Q3
Q2 2023 549,695 -105,519,100 -99% 01 Apr 2023 30 Jun 2023 10-Q 14 Aug 2024 2024 Q2
Q1 2023 3,751,468 -101,778,304 -96% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 3,545,691 -87,344,370 -96% 01 Oct 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
Q3 2022 106,689,924 +4,364,686 +4.3% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 106,068,795 +18,073,348 +21% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2023 2023 Q2
Q1 2022 105,529,772 +36,476,440 +53% 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q4 2021 90,890,061 01 Oct 2021 31 Dec 2021 10-K 10 Mar 2023 2022 FY
Q3 2021 102,325,238 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 87,995,447 01 Apr 2021 30 Jun 2021 10-Q 05 Aug 2022 2022 Q2
Q1 2021 69,053,332 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2017 7,737,000 +2,135,000 +38% 01 Jan 2017 31 Mar 2017 10-Q 11 May 2017 2017 Q1
Q1 2016 5,602,000 -42,031,000 -88% 01 Jan 2016 31 Mar 2016 10-Q 11 May 2017 2017 Q1
Q2 2015 50,414,000 +12,507,000 +33% 01 Apr 2015 30 Jun 2015 10-Q 05 Aug 2015 2015 Q2
Q1 2015 47,633,000 01 Jan 2015 31 Mar 2015 10-Q 09 May 2016 2016 Q1
Q2 2014 37,907,000 +5,082,000 +15% 01 Apr 2014 30 Jun 2014 10-Q 05 Aug 2015 2015 Q2
Q2 2013 32,825,000 01 Apr 2013 30 Jun 2013 10-Q 11 Aug 2014 2014 Q2

SEELOS THERAPEUTICS, INC. Annual Weighted Average Number of Shares Outstanding, Diluted (shares)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 4,900,222 +1,354,531 +38% 01 Jan 2023 31 Dec 2023 10-K 06 Mar 2024 2023 FY
2022 3,545,691 -87,344,370 -96% 01 Jan 2022 31 Dec 2022 10-K 06 Mar 2024 2023 FY
2021 90,890,061 01 Jan 2021 31 Dec 2021 10-K 10 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.